BACK · As filed with the SEC
IMAC Holdings income statement, by fiscal year
The statement as IMAC Holdings presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations · USD, except per-share amounts
| USD, except per-share amounts | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | Year ended Dec 31, 2018 Year ended Dec 31, 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | 72,050 | — | 16,185,682 | 14,385,828 | 12,835,198 | 15,126,026 | 6,701,071 |
| Others Income | — | — | — | 6,092 | — | — | — |
| Management Service | — | — | — | 216,068 | 12,487 | 25,318 | 64,000 |
| Health Care, Patient Service | — | — | 16,185,682 | 14,163,668 | 12,822,711 | — | — |
| Cost of Revenue | 305,248 | — | — | — | — | — | — |
| Gross profit (loss) | (233,198) | — | — | — | — | — | — |
| Operating expenses: | |||||||
| Patient expenses | — | — | 1,508,408 | 1,628,206 | 1,623,999 | 2,540,323 | 933,907 |
| Labor and Employee Benefits | — | 1,348,382 | 14,517,253 | 12,739,283 | 10,495,284 | 10,523,409 | 4,730,035 |
| Stock-Based Compensation Expense | — | — | — | 570,513 | 392,050 | 392,217 | 14,998 |
| Marketing Expense | — | 7,732 | 1,100,422 | 1,324,715 | 933,338 | 1,238,352 | 859,191 |
| Grant funds | — | — | — | — | (415,978) | — | — |
| Selling, General and Administrative Expense | 5,390,069 | 1,459,372 | 7,281,473 | 6,422,818 | 4,556,554 | 5,064,437 | 3,063,270 |
| Depreciation Expense | — | 126,138 | 1,626,614 | 1,649,187 | 1,722,465 | 1,552,919 | 651,066 |
| Loss on disposition or impairment | — | 3,433,884 | 8,431,803 | 149,464 | — | — | — |
| Total operating expenses | 5,390,069 | 6,375,508 | 34,465,974 | 24,484,186 | 19,307,712 | 21,311,657 | 10,252,467 |
| Operating loss | (5,623,267) | (6,375,508) | (18,280,292) | (10,098,358) | (6,472,514) | (6,185,631) | (3,551,396) |
| Other income (expense): | |||||||
| Interest Income | — | — | — | 2,885 | 6,073 | 7,794 | 7,541 |
| Non-Operating Income (Expense) | — | — | — | 57,329 | — | — | — |
| Interest Expense | — | — | — | — | 1,550,843 | — | — |
| Non-Operating Income (Expense) | — | — | — | — | (63,779) | — | — |
| Interest and Dividend Income (Non-Bank) | 3,470 | 27,156 | 10,583 | — | — | — | — |
| Non-Operating Income (Expense) | — | (2,040) | (28,905) | — | 6 | (16,132) | 18,356 |
| Beneficial conversion interest expense | — | — | — | — | — | (639,159) | — |
| Non-Operating Income (Expense) | — | — | — | — | — | 140,074 | — |
| Interest expense | — | (124,966) | (14,191) | (504,103) | (563,067) | (258,535) | (153,824) |
| Interest expense | (677,981) | — | — | — | — | — | — |
| Total other income (expenses) | (674,511) | (99,850) | (32,513) | (443,889) | 930,076 | (765,958) | (127,927) |
| Loss before equity in earnings (loss) of non-consolidated affiliate | — | — | — | — | — | (6,951,589) | (3,679,323) |
| Income from Equity Method Investments | — | — | — | — | — | — | (105,550) |
| Net loss before income taxes | (6,297,778) | (6,475,358) | (18,312,806) | (10,542,247) | (5,542,438) | (6,951,589) | (3,784,873) |
| Net loss | — | — | — | (10,542,247) | (5,542,438) | (6,951,589) | (3,784,873) |
| Net loss attributable to non-controlling interest | — | — | — | — | 538,705 | 454,359 | 731,130 |
| Basic and diluted | — | — | — | (0.47) | (0.45) | (0.84) | (0.47) |
| Basic and diluted | — | — | — | 22,551,699 | 11,050,144 | 7,753,642 | 4,533,623 |
| Net loss from continuing operations | — | (6,475,358) | — | — | — | — | — |
| Net loss from continuing operations | (6,297,778) | — | — | — | — | — | — |
| Extraordinary Items | (2,648,008) | (1,707,342) | — | — | — | — | — |
| Extraordinary Items | (100,041) | (1,235,885) | — | — | — | — | — |
| Income from Discontinued Operations | (2,748,049) | (2,943,227) | — | — | — | — | — |
| Net loss | (9,045,827) | (9,418,585) | (18,312,806) | — | (5,003,733) | (6,497,230) | (3,053,743) |
| Preferred dividends | (1,250,979) | — | — | — | — | — | — |
| Net loss available to common stockholders | (10,296,806) | — | — | — | — | — | — |
| Net loss per share from continuing operations basic | (4.01) | (5.82) | — | — | — | — | — |
| Net loss per share from continuing operations diluted | (4.01) | (5.82) | — | — | — | — | — |
| Loss per share from discontinued operations - Basic | (1.75) | (2.65) | — | — | — | — | — |
| Loss per share from discontinued operations - diluted | (1.75) | (2.65) | — | — | — | — | — |
| Earnings Per Share (Basic) | (5.76) | (8.47) | (0.65) | — | — | — | — |
| Earnings Per Share (Diluted) | (5.76) | (8.47) | — | — | — | — | — |
| Weighted Average Shares Outstanding | 1,569,627 | 1,111,844 | 28,273,884 | — | — | — | — |
| Weighted Average Shares Outstanding, Diluted | 1,569,627 | 1,111,844 | — | — | — | — | — |
| Total patient revenue, net | — | — | — | — | — | 15,100,708 | 6,637,071 |
| Patient Revenues | — | — | — | — | — | — | 16,135,967 |
| Contractual Adjustments | — | — | — | — | — | — | (9,498,896) |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.